MADRIGAL PHARMACEUTICALS, INC.
MDGLCIK 0001157601 · Pharmaceutical Preparations · Nasdaq
- MADRIGAL PHARMACEUTICALS, INC. (until 2026-06-17)
- SYNTA PHARMACEUTICALS CORP (until 2016-08-01)
Revenue (TTM)
$948.66M
+432.1% YoY
Q1 May 2026
Net Income (TTM)
−$324.1M
+38.1% YoY
Q1 May 2026
EPS Diluted (TTM)
−$11.37
+41.3% YoY
Q1 May 2026
Gross Margin
99.3%
Q1 May 2026
Operating Margin
-35.1%
Q1 May 2026
Net Margin
-34.2%
Q1 May 2026
Free Cash Flow (TTM)
−$493.79M
Q1 May 2026
Cash
$227.03M
Q1 May 2026
Total Debt
$340.33M
Q1 May 2026
Shares Outstanding
23.06M sh
Q1 May 2026
Revenue & Net Income
EPS (Diluted)
Margins
Cash Flow
Revenue Growth (YoY)
Balance Sheet
Cash vs Debt
Latest news
All news →-
Routine Neutral
Madrigal Pharmaceuticals (MDGL) Adopts Equity Incentive Plan
The company filed details of its stock compensation program allowing awards of options, restricted stock, and other equity instruments.